Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.